ProQR Therapeutics (NASDAQ:PRQR) versus BetterLife Pharma (OTCMKTS:BETRF) Head to Head Contrast

ProQR Therapeutics (NASDAQ:PRQR) and BetterLife Pharma (OTCMKTS:BETRF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ProQR Therapeutics and BetterLife Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	0	0	4	1	3.20
BetterLife Pharma	0	0	0	0	0.00

ProQR Therapeutics currently has a consensus price target of $7.60, suggesting a potential upside of 195.72%. Given ProQR Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than BetterLife Pharma.

Insider & Institutional Ownership

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of BetterLife Pharma shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 34.8% of BetterLife Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

ProQR Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, BetterLife Pharma has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Valuation and Earnings

This table compares ProQR Therapeutics and BetterLife Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.88 million	11.74	-$30.43 million	($0.32)	-8.03
BetterLife Pharma	N/A	N/A	-$2.14 million	($0.03)	-2.40

BetterLife Pharma has lower revenue, but higher earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than BetterLife Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProQR Therapeutics and BetterLife Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-134.31%	-71.58%	-19.70%
BetterLife Pharma	N/A	N/A	-998.84%

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

About BetterLife Pharma

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.